Abstract | BACKGROUND: Risk stratification with specific biomarkers is proposed for tailored P2Y12 inhibitor therapy in patients with STEMI. METHODS: RESULTS: MACCE incidence was lower in the ticagrelor group than in the clopidogrel group (0.8% versus 1.2%; P=0.046), but under different NT-proBNP levels, cumulative hazards of MACCE were without statistical significance. Bleeding rates were higher in the ticagrelor group than in the clopidogrel group (all bleeding: 9.9% versus 6.9%, P<0.001; major bleeding: 4.0% versus 2.7%, P<0.001). The higher cumulative hazard of bleeding could be identified in the Kaplan-Meier curves. In the multivariate analysis, ticagrelor increased bleeding events, compared with clopidogrel, at NT-proBNP >1800 ng/L patients (all bleeding: HR 1.46; 95%CI, 1.07-2.01; major bleeding: HR 1.68, 95%CI, 1.03-2.74), but a low effect was found in those with lower NT-proBNP level. Subgroup analyses show that ticagrelor increased major bleeding in patients with left ventricular ejection fraction (LVEF) <0.50 (HR 3.29; 95% CI 1.61-6.74) (interaction p=0.03). CONCLUSION:
|
Authors | Xin Zhao, Guannan Ai, Miaohan Qiu, Xiaozeng Wang, Lei Zhang, Xiaoxu Yang, Yifei Liu, Pei Xu, Jiyuan Zhang, Chonghuai Gu, Mengge Zhou, Yongchen Hao, Dong Zhao, Yaling Han, CCC investigators |
Journal | International journal of cardiology
(Int J Cardiol)
Vol. 310
Pg. 1-8
(07 01 2020)
ISSN: 1874-1754 [Electronic] Netherlands |
PMID | 32307186
(Publication Type: Journal Article)
|
Copyright | Copyright © 2020 Elsevier B.V. All rights reserved. |
Chemical References |
- Peptide Fragments
- Platelet Aggregation Inhibitors
- pro-brain natriuretic peptide (1-76)
- Natriuretic Peptide, Brain
- Clopidogrel
- Ticagrelor
|
Topics |
- Acute Coronary Syndrome
(diagnosis, drug therapy)
- Clopidogrel
(adverse effects)
- Humans
- Natriuretic Peptide, Brain
- Peptide Fragments
- Percutaneous Coronary Intervention
- Platelet Aggregation Inhibitors
(adverse effects)
- ST Elevation Myocardial Infarction
(diagnostic imaging, drug therapy)
- Stroke Volume
- Ticagrelor
(adverse effects)
- Treatment Outcome
- Ventricular Function, Left
|